The most effective peptides for weight loss available in South Africa in 2026 are semaglutide (Ozempic), tirzepatide (Mounjaro), and liraglutide (Saxenda). All three are SAHPRA-registered, prescription-only medicines backed by phase 3 clinical data showing 15β22% mean body-weight reductions [1][8][12].
What This Article Covers
The five peptides South Africans are most actively researching in 2026, their mechanisms of action, clinical evidence, local pricing, and how to distinguish between SAHPRA-registered options and unverified research compounds. You'll find the cost trade-offs between semaglutide and tirzepatide, why retatrutide remains unavailable locally, and which metabolic peptides lack meaningful human trial support.
- Semaglutide (Ozempic / Wegovy), GLP-1 agonist; R2,700βR3,100/month; up to ~17% weight loss at 18 months [1][12]
- Tirzepatide (Mounjaro), dual GIP/GLP-1 agonist; ~R4,600/month at maintenance dose; up to ~22% weight loss at 72 weeks [4][8]
- Liraglutide (Saxenda), the only GLP-1 agonist SAHPRA has registered specifically for obesity [1][3]
- Retatrutide, triple agonist (GLP-1/GIP/glucagon); not yet SAHPRA-registered; 2023 phase 2 data showed ~24% weight loss at 48 weeks [9]
- AOD-9604 / MOTS-C, experimental peptides sold in a regulatory grey zone; no head-to-head human trial data against GLP-1 agonists as of 2025 [16]
A 2026 eNCA report pegged monthly costs for weight-management doses of semaglutide and tirzepatide at R3,000βR6,000, reflecting dose escalation and dispensing-fee variation across South African pharmacies [6].
Why Peptides for Weight Loss? The Science in 2026
GLP-1, GIP, and glucagon receptor agonists produce clinically meaningful weight loss by suppressing appetite through hypothalamic signalling, slowing gastric emptying, and improving insulin sensitivity. These mechanisms produce effects that diet and exercise alone cannot replicate at the same magnitude.
How These Peptides Signal the Brain to Eat Less
Glucagon-like peptide-1 (GLP-1) is a gut-derived hormone released after eating. Synthetic GLP-1 agonists like semaglutide bind to GLP-1 receptors in the hypothalamus and brainstem, reducing hunger signals and increasing satiety. The result is a sustained reduction in caloric intake without requiring conscious restriction.
Tirzepatide adds glucose-dependent insulinotropic polypeptide (GIP) agonism to this mechanism. In the SURMOUNT-1 trial, that dual action produced mean weight reductions of approximately 20β22% of baseline body weight at 72 weeks on 10β15 mg doses, compared with roughly 3% on placebo [2]. Retatrutide extends the model further by adding glucagon receptor agonism, which increases energy expenditure through thermogenic effects; a 2023 phase 2 trial reported up to 24% mean weight loss at 48 weeks [3].
Approved Medicines vs. Research Peptides
The distinction matters legally and practically. SAHPRA classifies GLP-1 and dual-agonist peptides as Schedule 4 prescription medicines when sold as registered products [1]. Saxenda (liraglutide) is the only GLP-1 agonist SAHPRA has registered specifically for obesity; Ozempic and Mounjaro carry diabetes registrations and are used for weight loss off-label [1].
Experimental compounds such as AOD-9604 and MOTS-C sit in a different category entirely. No published 2024β2025 clinical trial directly compares either compound against a GLP-1 agonist for human weight loss [13]. They are not SAHPRA-registered for any indication, and enforcement against consumer-facing therapeutic marketing has been increasing [1][6].
For South African adults weighing their options in 2026, the evidence hierarchy is clear: phase 3 trial data supports the registered GLP-1 and dual-agonist medicines; everything else sits at preclinical or early-phase evidence at best.
Semaglutide: The GLP-1 Standard for Weight Loss
Semaglutide is a GLP-1 receptor agonist that reduces body weight by suppressing appetite, slowing gastric emptying, and lowering caloric intake without requiring conscious dietary restriction. It is the most clinically validated peptide for obesity management available in South Africa in 2026 [1][15].
2026 South African pricing for semaglutide (SAHPRA-registered products):
- Ozempic 2 mg/1.5 ml pen (4 Γ 0.5 mg doses): approximately R1,346 per pen [3]
- Ozempic 4 mg/3 ml pen (4 Γ 1 mg doses): approximately R2,693 per pen [3]
- Monthly cost at weight-management doses: R2,700βR3,100 at standard 1 mg weekly dosing; R3,000βR6,000 at higher doses reflecting escalation and dispensing fees [1][17]
- Saxenda (liraglutide): the only GLP-1 agonist SAHPRA has registered specifically for obesity; Ozempic carries a diabetes registration and is used for weight loss off-label [1]
- Wegovy (semaglutide 2.4 mg, the dedicated obesity formulation): not separately registered in South Africa as of 2026; clinicians reference its STEP trial data when dosing Ozempic at equivalent levels [1]
Efficacy: What the Clinical Data Shows
In the STEP-1 trial, once-weekly subcutaneous semaglutide 2.4 mg produced a mean weight reduction of approximately 14.9% of baseline body weight at 68 weeks in adults with obesity, compared with 2.4% on placebo [15]. A 2024 review of incretin-based pharmacotherapy confirmed these results hold across diverse populations when combined with lifestyle modification [16]. Clinically noticeable weight loss typically appears within 4β8 weeks of starting treatment, with the bulk of reduction occurring over 6β12 months [4].
Dosing follows a structured escalation: patients begin at 0.25 mg weekly for four weeks, stepping up through 0.5 mg and 1 mg before reaching the 2.4 mg maintenance dose used in obesity trials. This titration schedule exists to reduce gastrointestinal side effects, which affect the majority of users to some degree during the first 8β12 weeks [13].
Side Effects and Suitability
The most common adverse effects across 2023β2024 clinical data are nausea, vomiting, diarrhoea, and constipation, predominantly during dose escalation [13]. Approximately 5β10% of patients discontinue due to tolerability issues in major obesity trials [13]. Semaglutide is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, based on rodent carcinogenicity data reflected in current SAHPRA-registered product information [1][13].
Semaglutide is suitable for adults with a BMI of 30 kg/mΒ² or above, or 27 kg/mΒ² with at least one weight-related comorbidity, consistent with the criteria used in STEP trial enrolment [15]. South African prescribers access it through services such as Online Doctor SA and Vivari Aesthetics, both of which dispense SAHPRA-registered originator product from Novo Nordisk [1][4]. For a full breakdown of available formulations and local supplier options, see our dedicated semaglutide hub. Readers comparing semaglutide against the dual-agonist option can review the tirzepatide page for side-by-side mechanism and pricing detail.
Tirzepatide: Dual GIP/GLP-1 for Stronger Results
Tirzepatide is a dual GIP/GLP-1 receptor agonist that produces greater mean weight loss than semaglutide in head-to-head and comparative trial data. SURMOUNT-1 (2022) recorded up to 22.5% mean body-weight reduction at 72 weeks on the 15 mg dose versus approximately 3% on placebo [6].
How the Dual Mechanism Works
Where semaglutide activates only the GLP-1 receptor, tirzepatide simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP agonism amplifies insulin secretion, reduces glucagon, and appears to enhance the appetite-suppressing and fat-oxidation effects of GLP-1 signalling. That combined action is why tirzepatide consistently outperforms single-agonist options in the same timeframe [5][6].
Dosing and Titration
Tirzepatide starts at 2.5 mg weekly for four weeks, then steps up in 2.5 mg increments every four weeks toward a maintenance dose of 10β15 mg weekly. This slow escalation mirrors the semaglutide titration rationale: minimising gastrointestinal side effects during the adjustment period [13].
Clinical Evidence
SURMOUNT-1 (published NEJM, 2022) enrolled adults with obesity and no diabetes. At 72 weeks, mean weight loss reached 15.0%, 19.5%, and 20.9% on the 5 mg, 10 mg, and 15 mg doses respectively, compared with 3.1% on placebo [6]. SURMOUNT-2 (2022) confirmed similar magnitude reductions in adults with type 2 diabetes [6]. No South African-specific obesity trials exist for tirzepatide; local clinicians reference these international datasets when prescribing off-label for weight management [13].
South Africa Availability and 2026 Pricing
Mounjaro (Eli Lilly) is SAHPRA-registered and available through services such as Online Doctor SA [13]. Spotlight pricing data (2025) places single-dose 2.5 mg and 5 mg pens at approximately R880 each, with higher-dose pens around R1,140, and a 10 mg maintenance regimen costing roughly R4,600 per month [2][13]. A 2026 eNCA summary reported weight-management doses of tirzepatide generally falling in the R3,000βR6,000 per month range once escalation is factored in [12].
2026 tirzepatide pricing at a glance (South Africa):
- 2.5 mg single-dose pen: approximately R880 (2025 data) [13]
- 5 mg single-dose pen: approximately R880 (2025 data) [13]
- Higher-dose pens (7.5β10 mg): approximately R1,140 per pen (2025 data) [13]
- 10 mg monthly maintenance: approximately R4,600 per month (2025 data) [2][13]
- Typical escalation range: R3,000βR6,000 per month (2026 estimate) [12]
Side Effects
The side-effect profile closely resembles semaglutide's: nausea, diarrhoea, vomiting, and constipation are most common during dose escalation. Pooled 2022β2024 data suggest tirzepatide may carry slightly higher rates of nausea and diarrhoea at maximal doses, along with injection-site reactions and mild transient heart-rate increases [11]. The same thyroid carcinoma and MEN2 contraindications that apply to GLP-1 agonists are reflected in Mounjaro's SAHPRA-registered product information [13].
For a detailed mechanism comparison, see the semaglutide hub, or review full product and supplier detail on the tirzepatide page.
Retatrutide: Triple-Agonist, Not Yet Registered
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. This mechanism combines appetite suppression, improved insulin sensitivity, and increased energy expenditure into a single weekly injection. The glucagon receptor activation is what separates it from tirzepatide and drives its higher weight-loss ceiling in early data.
What the Phase 2 Trial Actually Showed
A phase 2 trial published in the New England Journal of Medicine in 2023 reported mean weight loss of up to 24% of baseline body weight at 48 weeks in adults with obesity on the highest retatrutide doses [7]. That figure exceeds the 20β22% seen with tirzepatide at 72 weeks in SURMOUNT-1 [6], though direct comparison is complicated by different trial durations, populations, and titration schedules. As of 2025, phase 3 trials are ongoing; no large-scale outcomes data has been published [7][8].
Retatrutide is not approved for human therapeutic use in South Africa or most other jurisdictions as of 2026. SAHPRA has not registered any retatrutide product, placing it firmly outside the regulated medicine pathway that covers Ozempic and Mounjaro [3][9]. Any retatrutide sold locally occupies the same regulatory grey zone as other unregistered research peptides, and quality claims from online suppliers remain unverified [9].
2026 South African Pricing and Formulations
The following products appear in South African peptide-shop listings as of 2026. Pricing should be treated as **** given the absence of SAHPRA registration and publicly available certificates of analysis [5][9]:
- 32-dose Retatrutide pen (8 mg): pricing not confirmed in verified ZAR sources
- 64-dose Retatrutide pen: pricing not confirmed in verified ZAR sources
- HD Labs Retatrutide 10 mg vial: pricing not confirmed in verified ZAR sources
- Retatrutide 10 mg (generic label): a 2026 cost analysis describes retatrutide globally as "the newest and most expensive" triple agonist with rapidly changing pricing, but provides no South Africa-specific ZAR figures [5]
Typical dosing in the phase 2 trial ranged from 8 mg to 12 mg weekly, with some arms reaching 16 mg [7]. No South African clinical service currently offers retatrutide through a SAHPRA-compliant prescribing pathway comparable to those available for semaglutide or tirzepatide.
Approval Timeline
No regulatory submission date for retatrutide has been announced in South Africa as of 2026. Phase 3 completion and subsequent SAHPRA review would realistically place any registered product several years away. Buyers considering unregistered retatrutide should weigh three things: the absence of phase 3 safety data, no local batch-testing verification, and active SAHPRA enforcement against compounded and unregistered weight-loss peptides [9].
Combination Peptides: Tirsema & Cagrisema
Combination peptide formulations pair two distinct mechanisms in a single preparation, aiming to produce additive or synergistic weight loss beyond what either agent achieves alone.
Tirsema (Tirzepatide + Semaglutide)
Tirsema stacks tirzepatide's dual GIP/GLP-1 agonism with semaglutide's selective GLP-1 activity, theoretically amplifying appetite suppression and gastric-emptying delay. The rationale is that tirzepatide's GIP component and semaglutide's receptor-binding profile act on partially non-overlapping pathways, though no peer-reviewed phase 2 or 3 trial had confirmed this synergy in humans as of early 2026 [10]. South African peptide shops list products such as HD Tirsema 44 mg vials, but pricing is **** and no SAHPRA-registered Tirsema product exists [3][7].
Cagrisema (Cagrilintide + Semaglutide)
Cagrisema is a co-formulation of cagrilintide, a long-acting amylin analogue, with semaglutide. Amylin acts on the hindbrain to reduce meal size and slow gastric emptying via a pathway separate from GLP-1 receptors, the mechanistic basis for combining the two. Phase 2 data published in 2024 showed mean weight loss of approximately 15% at 32 weeks with cagrisema versus around 10% with semaglutide alone, though phase 3 results were still pending as of 2026 [10]. South African listings reference products such as Body Pharm Cagrisema pens, but ZAR pricing remains **** and no SAHPRA submission has been announced [3][7].
What Buyers Should Know
Both combinations occupy the same unregistered, grey-zone status as other experimental peptides in South Africa [3]. No local batch-testing verification or SAHPRA-compliant prescribing pathway exists for either formulation. The emerging 2024β2025 clinical data for cagrisema is genuinely promising, but "promising phase 2 results" and "proven, registered therapy" are not the same thing. Treat any supplier pricing as unverified until certificates of analysis from accredited laboratories are produced.
Metabolic Peptides: MOTS-C, AOD-9604 & HGH
MOTS-C, AOD-9604, and recombinant human growth hormone (somatropin) target fat metabolism through pathways entirely separate from GLP-1 receptors. The clinical evidence supporting their use for weight loss is substantially weaker than what exists for semaglutide or tirzepatide.
MOTS-C
MOTS-C is a mitochondrial-derived peptide that regulates glucose uptake and fatty acid oxidation by activating AMPK signalling in skeletal muscle. The foundational mechanistic data comes from a 2015 preclinical study in rodents [3]; as of early 2026, no published phase 2 or phase 3 human trial has evaluated MOTS-C against a GLP-1 agonist for weight loss outcomes [3][4]. South African peptide shops list Body Pharm MOTS-C 10 mg vials, but ZAR pricing remains **** and no SAHPRA-registered MOTS-C product exists [5][6].
AOD-9604
AOD-9604 is a synthetic fragment of the human growth hormone C-terminus (residues 176β191), designed to stimulate lipolysis without the insulin-resistance effects associated with full-length HGH. Australia's TGA reviewed AOD-9604 in 2013 and did not approve it for obesity, citing an uncertain clinical benefit profile [2]. No 2024β2025 pharmacotherapy review identifies AOD-9604 as an evidence-based alternative to GLP-1 agonists [4][9]. Body Pharm AOD-9604 2 mg vials appear on local listings; pricing is ****.
Somatropin (Recombinant HGH)
Somatropin is recombinant human growth hormone used clinically for diagnosed GH deficiency, not obesity. Its relevance to weight loss is indirect: it supports lean mass preservation and reduces visceral fat in GH-deficient patients, but these effects do not translate to meaningful fat loss in people with normal GH levels. Body Pharm somatropin is listed in two formats locally (a 40 IU pen and a 100 IU kit) with pricing **** in both cases.
How These Compare to GLP-1 Options
No head-to-head clinical trial comparing MOTS-C or AOD-9604 with semaglutide or tirzepatide in humans had been published as of 2025 [3][4]. Tirzepatide produced mean weight loss of roughly 20β22% at 72 weeks in SURMOUNT-1 [7]; no equivalent human dataset exists for either metabolic peptide. Buyers considering these alternatives alongside registered options such as semaglutide or tirzepatide should weigh that disparity in evidence directly. Any supplier marketing MOTS-C or AOD-9604 as equivalent or superior to GLP-1 agonists for weight loss is making a claim not grounded in contemporary comparative trials [3][4].
Thermogenic Agents: Clenbuterol & Yohimbine
Clenbuterol and yohimbine are not peptides in the strict biochemical sense, but they appear consistently alongside peptide stacks in South African research-chemical catalogues, so they warrant a direct assessment here.
Clenbuterol
Clenbuterol is a beta-2 adrenergic agonist that raises core body temperature and resting metabolic rate by stimulating beta-2 receptors in adipose and muscle tissue. In South Africa, it is registered as a veterinary bronchodilator, not a human weight-loss agent. SAHPRA has not approved any clenbuterol formulation for human obesity treatment, and human therapeutic marketing falls outside its registered medicine list [3][4]. Body Pharm lists two formulations locally: BP Clenbuterol 40 mcg tablets and BP Aqua Clen 80 mcg injectable solution; pricing for both is **** as of 2026. Cardiac arrhythmia, tachycardia, and hypokalaemia are documented adverse effects in human case reports, and these risks are not offset by any approved clinical indication for fat loss.
Yohimbine
Yohimbine is an alpha-2 adrenergic antagonist derived from the bark of Pausinystalia yohimbe. By blocking alpha-2 receptors, it reduces the inhibitory signal that suppresses fat mobilisation, particularly in stubborn adipose depots. A 2020 systematic review found modest, inconsistent fat-loss effects in small human trials, with no large randomised controlled trial confirming clinically meaningful weight reduction. Body Pharm lists BP Yohimba 10 mg capsules locally; pricing is **** as of 2026. Anxiety, elevated blood pressure, and palpitations are the most commonly reported adverse effects, and yohimbine is contraindicated in patients with hypertension or anxiety disorders.
Regulatory Position and Evidence Gap
Neither clenbuterol nor yohimbine appears in any 2023β2025 pharmacotherapy guideline as a recommended weight-loss intervention [11][15]. No head-to-head data compares either agent with GLP-1 agonists for obesity outcomes. Tirzepatide produced mean weight loss of approximately 20β22% at 72 weeks in SURMOUNT-1 (2022) [14]; neither thermogenic agent approaches that benchmark in any published human dataset. Buyers weighing these options against evidence-based alternatives such as semaglutide or tirzepatide should factor that gap in directly.
Comparison Table: Mechanism, Dosing & 2026 Pricing
Six weight-loss peptides and agents reviewed in this article are compared below across mechanism, dosing, expected outcomes, research status, and 2026 South African pricing.
| Peptide / Agent | Mechanism | Typical Weekly Dose | Expected Weight Loss | Research Status | 2026 ZAR Price (approx.) | Best For |
|---|---|---|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist, suppresses appetite, slows gastric emptying | 0.25β2.4 mg SC weekly | ~15β17% body weight at 12β18 months [14] | Phase 3 complete; SAHPRA-registered (Ozempic/Saxenda) [3] | R2,700βR6,000/month [1][3] | Adults with obesity or type 2 diabetes under medical supervision |
| Tirzepatide | Dual GIP/GLP-1 agonist, greater insulin sensitisation and appetite suppression than GLP-1 alone | 2.5β15 mg SC weekly | ~20β22% body weight at 72 weeks [8] | Phase 3 complete; SAHPRA-registered (Mounjaro) [4] | R880βR4,600/month [4][3] | Adults seeking greater percentage weight loss than semaglutide alone |
| Retatrutide | Triple GLP-1/GIP/glucagon agonist, adds thermogenic glucagon signalling | Investigational; phase 3 dosing TBC | ~24% body weight at 48 weeks (phase 2) [9] | Phase 2 published 2023; phase 3 ongoing; not SAHPRA-registered [5] | ****, no SA ZAR pricing confirmed [5] | Research context only; not available as a registered SA product |
| MOTS-C | Mitochondrial-derived peptide, activates AMPK, improves insulin sensitivity | No established human dose | Preclinical rodent data only [17] | No completed human obesity RCTs [18] | ****, grey-market suppliers only | Research interest; no clinical weight-loss indication |
| Clenbuterol | Beta-2 adrenergic agonist, raises metabolic rate and core temperature | Not established for fat loss | No large human RCT data for weight loss | No approved obesity indication; SAHPRA Schedule 4 [3] | **** locally | Not recommended for weight loss |
| Yohimbine | Alpha-2 adrenergic antagonist, reduces inhibitory signal on fat mobilisation | 5β20 mg oral daily (studied range) | Modest, inconsistent effects in small trials [15] | No large RCT confirming clinically meaningful reduction | **** locally | Contraindicated in hypertension or anxiety disorders |
Pricing Note
Semaglutide and tirzepatide are the only agents with confirmed 2026 ZAR pricing from SAHPRA-registered South African sources. Tirzepatide is the most cost-variable option, ranging from approximately R880 per low-dose pen to R4,600 per month at maintenance doses [4][3]. All other agents in this table carry **** local pricing as of 2026.
How to Choose the Right Peptide for Your Goals
Your choice should be driven by five concrete factors: your target weight reduction, acceptable timeline, monthly budget, tolerance for side effects, and how comfortable you are with agents that carry limited human trial data.
Weight-Loss Target and Timeline
If your goal is a clinically meaningful 10β15% reduction over 6β12 months and you want the strongest available evidence base, semaglutide is the logical starting point. STEP trial data published in 2021 shows mean losses of roughly 15% at 68 weeks on 2.4 mg weekly [17], and it is available through SAHPRA-registered channels at approximately R2,700βR3,100 per month [3].
If you want 20β22% body-weight reduction and are prepared to pay more, tirzepatide is the stronger performer. SURMOUNT-1 data from 2022 shows mean losses reaching that range at 72 weeks on 10β15 mg doses [14], with South African pricing ranging from roughly R880 per low-dose pen to R4,600 per month at maintenance [3].
Budget Constraints
Tirzepatide at maintenance doses costs up to R4,600 per month [3]. Semaglutide sits closer to R3,000 per month at weight-management doses [2]. Both are significant ongoing expenses, and neither is typically covered by medical schemes for an obesity indication [3].
Research Status Comfort Level
- Established evidence, SAHPRA-registered: Semaglutide or tirzepatide, both have completed phase 3 obesity trials and verified local supply chains [1][3].
- Frontier research, not yet registered: Retatrutide showed 24% mean weight loss at 48 weeks in a 2023 phase 2 trial [10], but carries no SAHPRA registration and no confirmed ZAR pricing as of 2026 [7].
- Preclinical only: MOTS-C has no completed human obesity RCTs [13]; any supplier marketing it for weight loss in South Africa should be treated as unverified.
- Not recommended for weight loss: Clenbuterol and yohimbine lack large RCT support for fat reduction and carry meaningful cardiovascular risks, particularly in patients with hypertension [9].
Existing Health Conditions
Patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome are contraindicated for GLP-1 agonists as a class [9]. Anyone with hypertension or anxiety disorders should avoid yohimbine. A prescribing clinician, not a supplement retailer, is the appropriate person to make this call.
Semaglutide is the evidence-grounded default for first-time users; tirzepatide is the stronger option for those targeting greater percentage loss within the same timeframe [15][18].
Where to Buy Peptides in South Africa: Suppliers & Safety
For SAHPRA-registered weight-loss peptides, the safest sourcing route in South Africa is a licensed pharmacy dispensing originator products under a valid prescription [3][4].
SAHPRA-Registered Products: The Verified Path
Semaglutide (Ozempic) and tirzepatide (Mounjaro) are manufactured under GMP conditions by Novo Nordisk and Eli Lilly respectively, and every batch reaching South African pharmacies has passed SAHPRA's registration requirements [3][4]. Clinical services such as Online Doctor SA and Vivari Aesthetics act as prescribing and dispensing pathways for these products; they do not manufacture peptides themselves, so their quality assurance derives directly from the originator companies' certificates of analysis [1][6]. If you are pursuing either of these agents, a registered prescriber and a licensed pharmacy is the only legally sound route. Our dedicated semaglutide and tirzepatide pages cover formulation options and verified dispensing pathways in more detail.
Research Peptides: The Grey Zone
Unregistered peptides, including experimental agents like MOTS-C and AOD-9604, occupy a regulatory grey zone under SAHPRA rules [3][5]. Human therapeutic marketing of these compounds is not permitted, and enforcement tightened noticeably in 2025 following investigations into compounded GLP-1 formulations [5]. Any online supplier marketing "lab-grade" weight-loss peptides in South Africa should be treated as unverified unless it can produce:
- A current certificate of analysis from an accredited third-party laboratory
- Documented batch numbers traceable to that COA
- Evidence of SAHPRA compliance or a clear research-use disclaimer
- Transparent contact details and a physical South African address
No public 2024β2026 sources confirm that independent local peptide shops meet all four criteria for experimental compounds [3][5].
Red Flags to Avoid
Suppliers that list no documentation, quote prices without batch references, or claim their products are "equivalent to Ozempic" without regulatory backing should be avoided outright [5]. Storage requirements for peptide integrity (typically 2β8 Β°C for reconstituted vials) are rarely communicated by unverified sellers, which compounds the quality risk. SAHPRA is the correct body to verify any supplier's registration status before purchase [3].
Side Effects & Safety Considerations
GLP-1 agonists cause gastrointestinal side effects in the majority of users, with nausea, vomiting, diarrhoea, constipation, and abdominal pain occurring most frequently during dose escalation. These effects are typically mild to moderate and diminish over time, but approximately 5β10% of patients in major obesity trials discontinued treatment due to tolerability issues [4].
GLP-1 and Dual-Agonist Side Effects
For both semaglutide and tirzepatide, the GI side-effect profile is broadly similar, though pooled 2022β2024 data suggest tirzepatide at maximal doses may produce slightly higher rates of nausea and diarrhoea, along with injection-site reactions and mild transient increases in heart rate [4][12]. South African clinicians managing obesity programmes emphasise slow dose-up titration and close monitoring of gallbladder and pancreatic symptoms as standard practice [3].
Serious adverse events are less common but require awareness:
- Gallbladder disease, elevated risk documented across the GLP-1 class in 2023β2024 product information for Saxenda, Ozempic, and Mounjaro [4]
- Pancreatitis, possible association; patients with a history of pancreatitis should discuss this risk with their prescriber before starting [4]
- Thyroid C-cell tumours, observed in rodent studies; standard contraindications apply for anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome [4]
- Pregnancy, GLP-1 agonists are not indicated during pregnancy; effective contraception is recommended for women of childbearing age on these agents [4]
Triple Agonists and Research Peptides
Retatrutide's phase 2 trial (published in NEJM, 2023) reported GI side effects alongside an increased incidence of tachycardia and modest blood pressure decreases, attributed to glucagon-related thermogenic and cardiovascular activity [5]. The 2024β2025 safety reading classifies these as manageable with careful titration, but phase 3 data are not yet complete [5][12].
Unregistered research peptides such as MOTS-C and AOD-9604 carry inherent unknowns: no 2024β2025 head-to-head safety comparisons with GLP-1 agents exist, and no large randomised human trials have characterised their adverse-event profiles [18]. Purchasing these compounds from unverified suppliers adds a further layer of risk, since storage integrity and batch purity cannot be confirmed without accredited certificates of analysis [3].
Any new or worsening abdominal pain, persistent vomiting, palpitations, or jaundice warrants prompt medical review.
Frequently Asked Questions
- Are peptides legal in South Africa? SAHPRA classifies GLP-1 peptides such as semaglutide and tirzepatide as Schedule 4 prescription medicines; registered products (Ozempic, Mounjaro, Saxenda) are legal when dispensed under medical supervision. Unregistered "research peptides" like MOTS-C and AOD-9604 occupy a regulatory grey zone, human therapeutic marketing is not permitted, and enforcement has been tightening since 2025 [3].
- How long before I see results? Semaglutide typically produces clinically noticeable weight loss within 4β8 weeks, reaching roughly 10β15% of baseline body weight by six months [14][15]. Tirzepatide shows significant separation from placebo by weeks 4β8, with mean losses of approximately 15β18% by 40β52 weeks on higher doses [7][9].
- Can I combine peptides? No published 2024β2025 human trial supports combining GLP-1 agonists with research peptides such as AOD-9604 or MOTS-C; doing so without medical supervision carries uncharacterised risks [18].
- What does it cost per month? As of 2025β2026, semaglutide (Ozempic) runs approximately R2,700βR3,100 per month, while tirzepatide (Mounjaro) costs roughly R4,000βR4,600 per month at maintenance doses [1][5].
- Do I need a prescription? Yes. All SAHPRA-registered GLP-1 products require a valid prescription from a registered South African healthcare practitioner [3][4].
- How do I store peptides? Originator pens (Ozempic, Mounjaro) must be refrigerated at 2β8 Β°C before first use; after first use, Ozempic pens may be kept below 30 Β°C for up to 56 days, per manufacturer labelling [4]. Unregistered research peptides have no SAHPRA-verified storage guidelines, adding a further quality-assurance risk [3].
Key Takeaways
- Semaglutide and tirzepatide are the only SAHPRA-registered, evidence-backed weight-loss peptides available in South Africa in 2026. Semaglutide produces ~15% mean weight loss at 68 weeks; tirzepatide produces ~20β22% at 72 weeks. Both require a valid prescription and cost R2,700βR6,000 per month depending on dose and supplier.
- Retatrutide showed 24% mean weight loss in a 2023 phase 2 trial but remains unregistered in South Africa. Phase 3 trials are ongoing, and no SAHPRA-compliant prescribing pathway exists locally.
- Unregistered research peptides (MOTS-C, AOD-9604, cagrisema, tirsema) lack head-to-head human trial data against GLP-1 agonists. Any supplier marketing these as equivalent to semaglutide or tirzepatide is making an unsubstantiated claim.
- Clenbuterol and yohimbine are not peptides and carry cardiovascular risks without evidence of clinically meaningful weight loss. Neither appears in current pharmacotherapy guidelines for obesity.
- GLP-1 and dual-agonist side effects (nausea, diarrhoea, vomiting) are common during dose escalation but typically diminish over 8β12 weeks. Approximately 5β10% of patients discontinue due to tolerability.
- Always source SAHPRA-registered peptides through a licensed pharmacy under a valid prescription. Unregistered suppliers cannot provide verified certificates of analysis or SAHPRA compliance.
Next Steps
Start by consulting a registered South African healthcare practitioner who can assess your BMI, comorbidities, and medical history. For SAHPRA-registered options, visit our dedicated semaglutide or tirzepatide pages to review formulations, verified local suppliers, and detailed prescribing information. If you are interested in experimental agents, ask your prescriber about ongoing clinical trials or research pathways in South Africa. Do not purchase unregistered peptides from online suppliers without verified certificates of analysis and transparent contact information.